Top Page
Fusion Antibodies Plc
(LSE:FAB)
Fusion Antibodies Plc (FAB) vs. S&P 500 (SPY)
Fusion Antibodies Plc Business Overview & Revenue Model
Fusion Antibodies Plc Financial Statement Overview
| Breakdown | |||||
| TTM | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 | Mar 2020 |
|---|---|---|---|---|---|
| Income Statement | Total Revenue | ||||
| 1.80M | 1.14M | 2.90M | 4.80M | 4.17M | 3.90M | Gross Profit |
| 269.00K | -265.00K | 202.00K | 1.72M | 1.31M | 1.15M | EBIT |
| -1.67M | -2.29M | -2.83M | -1.33M | -1.38M | -1.11M | EBITDA |
| -1.51M | -2.06M | -2.48M | -573.00K | -532.00K | -431.00K | Net Income Common Stockholders |
| -1.63M | -2.23M | -2.60M | -1.20M | -2.90M | -697.00K |
| Balance Sheet | Cash, Cash Equivalents and Short-Term Investments | ||||
| 1.20M | 1.20M | 195.00K | 2.05M | 2.69M | 1.54M | Total Assets |
| 2.42M | 2.42M | 2.06M | 4.92M | 5.83M | 6.04M | Total Debt |
| 43.00K | 43.00K | 75.00K | 69.00K | 230.00K | 380.00K | Net Debt |
| -1.16M | -1.16M | -120.00K | -1.98M | -2.46M | -1.16M | Total Liabilities |
| 627.00K | 627.00K | 939.00K | 1.23M | 1.08M | 1.23M | Stockholders Equity |
| 1.79M | 1.79M | 1.12M | 3.68M | 4.75M | 4.81M |
| Cash Flow | Free Cash Flow | ||||
| -1.17M | -1.77M | -1.87M | -591.00K | -1.52M | -275.00K | Operating Cash Flow |
| -1.17M | -1.77M | -1.75M | -333.00K | -1.15M | -166.00K | Investing Cash Flow |
| 2.00K | 1.00K | -114.00K | -258.00K | -365.00K | -109.00K | Financing Cash Flow |
| 1.12M | 2.77M | 7.00K | -46.00K | 2.67M | -172.00K |
Fusion Antibodies Plc Technical Analysis
Fusion Antibodies Plc Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
55 Neutral | £7.45M | 35.98 | 3.55% | ― | 56.29% | ― | |
52 Neutral | $5.15B | 3.05 | -44.13% | 2.84% | 16.42% | -0.48% | |
47 Neutral | £21.51M | ― | -87.30% | ― | ― | 71.17% | |
46 Neutral | £95.90M | ― | 167.16% | ― | -100.00% | -23.91% | |
44 Neutral | £7.34M | ― | -222.16% | ― | 24.71% | 38.28% | |
44 Neutral | £6.93M | ― | -129.49% | ― | 14.12% | 78.16% |
Fusion Antibodies Plc Corporate Events
Fusion Antibodies plc has announced that its issued share capital consists of 113,318,140 ordinary shares, each with one voting right. This information is crucial for shareholders to determine their interests in the company’s share capital under the FCA’s Disclosure Guidance and Transparency Rules. The announcement reflects the company’s commitment to transparency and provides stakeholders with essential data for financial decision-making.
Spark’s Take on GB:FAB Stock
According to Spark, TipRanks’ AI Analyst, GB:FAB is a Neutral.
Fusion Antibodies Plc’s overall stock score is low due to significant financial challenges, including declining revenues and persistent losses. While technical analysis indicates potential support levels, the bearish momentum and unattractive valuation further weigh down the score. Positive corporate events provide some optimism for future growth, but the immediate financial health remains a primary concern.
To see Spark’s full report on GB:FAB stock, click here.
Fusion Antibodies plc has received approval for a significant InnovateUK Launchpad grant, in collaboration with Queens University Belfast, to develop a humanised therapeutic DR5 antibody aimed at combating treatment-resistant cancers. The grant, totaling over £808k with up to £545k allocated to Fusion, will support the project over 18 months, covering labor, materials, and overheads. This initiative is expected to enhance Fusion’s market positioning by providing case study data for marketing its technologies and potentially licensing the therapeutic asset to third-party pharmaceutical companies, thereby demonstrating its scientific capabilities and strengthening its industry presence.
Spark’s Take on GB:FAB Stock
According to Spark, TipRanks’ AI Analyst, GB:FAB is a Neutral.
Fusion Antibodies Plc is facing substantial financial hurdles, with declining revenues and significant losses. Technical analysis indicates bearish momentum, and valuation metrics highlight unprofitability. Despite these challenges, recent corporate events, including successful fundraising and strategic collaborations, offer some optimism for future growth. However, the immediate financial health remains a primary concern, resulting in a low overall stock score.
To see Spark’s full report on GB:FAB stock, click here.
Fusion Antibodies PLC, a company operating in the biotechnology sector, has announced a change in its major shareholdings. Canaccord Genuity Group Inc., based in Vancouver, Canada, has acquired a significant percentage of voting rights in Fusion Antibodies, reaching a threshold of 7.1182%. This change is attributed to participation in a recent share placing by Fusion Antibodies, which was admitted to trading on AIM on April 9, 2025. The acquisition may impact the company’s market dynamics and stakeholder interests.
Spark’s Take on GB:FAB Stock
According to Spark, TipRanks’ AI Analyst, GB:FAB is a Neutral.
Fusion Antibodies Plc’s overall stock score is low due to significant financial challenges, including declining revenues and losses, as well as poor valuation metrics. Although technical indicators are mixed, the negative P/E ratio and lack of dividend yield further weigh down the stock’s attractiveness. Recent corporate events, such as capital raises and strategic growth initiatives, provide some positive outlook but are insufficient to offset the immediate financial concerns.
To see Spark’s full report on GB:FAB stock, click here.
Fusion Antibodies Plc has announced a change in the breakdown of its voting rights, with Unicorn Asset Management Limited now holding 5.65% of the voting rights, down from a previous 6.71%. This adjustment in holdings may impact the company’s shareholder dynamics and influence its strategic decisions moving forward.
Spark’s Take on GB:FAB Stock
According to Spark, TipRanks’ AI Analyst, GB:FAB is a Neutral.
Fusion Antibodies Plc’s overall stock score is low due to significant financial challenges, including declining revenues and losses, as well as poor valuation metrics. Although technical indicators are mixed, the negative P/E ratio and lack of dividend yield further weigh down the stock’s attractiveness. Recent corporate events, such as capital raises and strategic growth initiatives, provide some positive outlook but are insufficient to offset the immediate financial concerns.
To see Spark’s full report on GB:FAB stock, click here.
Fusion Antibodies plc announced that all resolutions were passed at its recent general meeting, resulting in the successful raising of approximately £1.17 million through a Placing. The company has applied for the admission of 8,416,020 Second Tranche Placing Shares to trading on AIM, with trading expected to commence on 9 April 2025. This development increases the total number of ordinary shares to 113,318,140, enhancing the company’s market presence and potentially impacting shareholder interests under FCA rules.
Spark’s Take on GB:FAB Stock
According to Spark, TipRanks’ AI Analyst, (GB:FAB) is a Neutral.
Fusion Antibodies Plc is currently facing significant financial and operational challenges, reflected in declining revenues and persistent losses. Technical analysis indicates bearish momentum, while valuation metrics highlight unprofitability and a lack of income attractiveness. Despite positive corporate events aiming to strengthen growth potential, the company’s immediate financial health remains a primary concern, leading to a low overall stock score.
To see Spark’s full report on (GB:FAB) stock, click here.
Fusion Antibodies plc announced that its issued share capital consists of 104,902,120 ordinary shares, each with one voting right. This information is crucial for shareholders to determine their interests under the FCA’s Disclosure Guidance and Transparency Rules. The company’s growth strategy focuses on leveraging technological advances to expedite the drug development process, positioning itself as a key player in the pharmaceutical and diagnostic sectors.
Fusion Antibodies plc announced a conditional placing to raise approximately £1.17 million through the issuance of new ordinary shares. The funds will be used to enhance the company’s cash position, support research and development, and promote its OptiMAL® platform. The placing is divided into two tranches, with the second tranche contingent on shareholder approval at an upcoming general meeting. This financial move aims to capitalize on growth opportunities and improve the company’s market positioning, particularly in North America, while addressing the need for increased working capital.
Fusion Antibodies plc has secured a contract for a new stable Cell Line Development project with a US biotechnology company, expected to generate $250,000 in revenue by the end of 2025. This project underscores Fusion’s reputation for delivering high-quality therapeutic antibodies and is anticipated to provide a financial foundation for the fiscal year ending March 2026, with potential for future growth in cell line development projects.